The pharmaceutical industry is a key partner in Europe’s fight against disease, developing new treatments and cures for patients across Europe. It is imperative that Europe remains a competitive destination for medical research and development by maintaining, sustaining and developing a predictable, robust regulatory and innovation-supportive incentives environment.

Over the past decade, China has built 25,000 km of dedicated high-speed railway—more than the rest of the world combined. China’s High-Speed Rail Development examines the Chinese experience to draw lessons for countries considering investing in high-speed rail.